MSD Animal Health, presented multiple studies in support of the BRAVECTO® fluralaner portfolio at the 2025 World Association for the Advancement of Veterinary Parasitology Congress (WAAVP) in Curitiba, Brazil, August 17-21, 2025. Data presented highlights MSD Animal Health’s commitment to rapidly advance research across parasite prevention and treatment and build on its portfolio of established parasiticides.
“The new data we presented at WAAVP spotlight our commitment to parasitology research as we develop novel treatment approaches in our ongoing work to improve parasite prevention and treatment,” said Rafael Chiummo, Ph.D., Associate Director, Clinical Research, Latin America, MSD Animal Health. “MSD Animal Health is pioneering innovation in parasitology through research and development that benefits dogs and the people that care for them.”
BRAVECTO 365
A study titled “The Effectiveness of BRAVECTO® 365 (fluralaner 150 mg/ml suspension for injection) for the Control of Fleas on Naturally Infested Client-Owned Dogs in Brazil” evaluated the efficacy of the injectable formulation of BRAVECTO in treating naturally infested dogs with Ctenocephalides felis fleas in Brazil and found a 100% reduction in live fleas from Day 10 and that efficacy remained at or above 99.8% for 365 days for one full year. All dogs completed the trial without any treatment-related adverse events. This study demonstrated the high efficacy and safety of the injectable formulation of BRAVECTO against flea infestations on dogs over an entire year.
A study title “Long-Term Efficacy of BRAVECTO 365 (fluralaner 150 mg/ml suspension for injection) Against Rhipicephalus sanguineus (sensu lato) Ticks on Client-Owned Dogs in Brazil” assessed the effectiveness of BRAVECTO 365, administered subcutaneously at 15 mg fluralaner/kg body weight, in treating dogs naturally infested with Rhipicephalus sanguineus (commonly called Brown Dog ticks). Forty client-owned dogs with confirmed tick infestations received a single dose, and tick counts were monitored from before treatment up to 365 days post-treatment. Results demonstrated a ≥99.8% reduction in live ticks from Day 7 through Day 365.
BRAVECTO 1 MONTH TRIPLE
A study titled “Evaluation of a Chewable Tablet Containing Fluralaner + Moxidectin + Pyrantel for the Treatment of Demodectic Mange in Dogs” assessed the efficacy and safety of an oral combination tablet containing fluralaner, moxidectin, and pyrantel for treating Demodex canis mite infestations in naturally affected dogs. Twelve dogs confirmed positive for mites received two doses of the tablet 30 days apart, with mite counts monitored at multiple intervals up to 90 days. Results showed a progressive reduction in mite counts, reaching 99% by Day 33 and 100% from Day 37 onward. No treatment-related adverse effects were observed. The findings indicate that this combination tablet is both safe and highly effective for managing demodectic mange in dogs when two doses are administered at a monthly interval at the recommended dosage.
BRAVECTO 365:
- Clinical Evaluation of BRAVECTO® 365 (Fluralaner 150 Mg/ml Suspension for Injection) for Treating Naturally Infested Dogs with Otodectic Mange
- Evaluation Of BRAVECTO® 365 (Fluralaner 150 Mg/ml Suspension for Injection) for the Treatment of Demodectic Mange in Dogs
- Efficacy Against Ticks and Fleas Artificial Infestation (One Year Long)
- Onset of Efficacy Against Fleas and Ticks Artificial Infestation
BRAVECTO 1 MONTH TRIPLE:
- Successful Treatment of Canine Roundworm Infections with a Single Administration of a Fluralaner, Moxidectin and Pyrantel Chewable Tablet in a Non-Terminal Study Design
- Successful Treatment of Experimental Canine Hookworm Infections with a Single Administration of a Fluralaner, Moxidectin and Pyrantel Chewable Tablet in a Non-Terminal Study Design
- Field Study on the Effectiveness of Fluralaner, Moxidectin, and Pyrantel in Preventing Heartworm Infection in Client-Owned Dogs
